Global Intravitreal Injectable Market Growth (Status and Outlook) 2025-2031

Publication ID:

LPI08255577

Publication Date:

August 8, 2025

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

According to this study, the global Intravitreal Injectable market size will reach US$ 28490 million by 2031.
Intravitreal injectables are sterile pharmaceutical formulations administered directly into the vitreous humor of the eye using a fine needle. This route of administration allows for targeted delivery of medications鈥攕uch as anti-VEGF agents, corticosteroids, or antibiotics鈥攊nto the posterior segment of the eye, ensuring high local drug concentrations while minimizing systemic exposure. Intravitreal injections are commonly used to treat retinal diseases including age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and infectious endophthalmitis.
The global intravitreal injectable market has experienced steady growth in recent years, driven primarily by the rising prevalence of retinal disorders such as macular edema, age-related macular degeneration (AMD), and retinal vein occlusion (RVO). Leading pharmaceutical players in this space include Regeneron Pharmaceuticals (notably with Eylea), Allergan, EyePoint Pharmaceuticals, Genentech, and Kanghong Pharmaceutical. These top five companies collectively account for over 70% of global market share, reflecting a relatively concentrated competitive landscape. North America currently dominates the global market, holding a share of more than 50%, followed by Europe and Asia-Pacific, each with shares exceeding 40%.
In terms of drug types, anti-VEGF (vascular endothelial growth factor) therapies represent the largest and most significant market segment, contributing to over 85% of total market revenue. These agents are highly effective in inhibiting abnormal blood vessel growth in the retina, making them the standard of care for diseases like AMD and diabetic macular edema (DME). Other therapeutic classes such as corticosteroids and antibiotics play smaller roles, typically in more specialized or adjunctive treatment scenarios.
The largest clinical application of intravitreal injectables is for macular edema, which continues to see a rise in incidence linked to diabetes and aging populations worldwide. Macular degeneration and RVO are also major contributors to demand, reinforcing the importance of targeted ophthalmic treatments. The increase in awareness, earlier diagnosis, and improved accessibility to eye care services are further driving market expansion across both developed and emerging regions.
Looking ahead, the market is expected to grow steadily due to increasing disease burden and product innovation. Notably, new players such as Astellas Pharma have begun entering the market, signaling a shift toward broader competition and possibly next-generation therapies with extended efficacy and dosing intervals. Advances in drug delivery systems, longer-acting formulations, and biosimilars are expected to further shape the landscape and offer new growth opportunities.
The 鈥淚ntravitreal Injectable Industry Forecast鈥� looks at past sales and reviews total world Intravitreal Injectable sales in 2024, providing a comprehensive analysis by region and market sector of projected Intravitreal Injectable sales for 2025 through 2031. With Intravitreal Injectable sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Intravitreal Injectable industry.
This Insight Report provides a comprehensive analysis of the global Intravitreal Injectable landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Intravitreal Injectable portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Intravitreal Injectable market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Intravitreal Injectable and breaks down the forecast by Drug, by Disease, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Intravitreal Injectable.
This report presents a comprehensive overview, market shares, and growth opportunities of Intravitreal Injectable market by product type, application, key players and key regions and countries.
Segmentation by Drug:
Anti-VEGF
Steroids
Others
Segmentation by Disease:
Macular Degeneration
Macular Edema
Uveitis
Retinal Vein Occlusion
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Regeneron Pharmaceuticals (Eylea)
Allergan
EyePoint Pharmaceuticals
Genentech
Kanghong Pharmaceutical
Astellas Pharma
Clearside Biomedical
Bayer

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Intravitreal Injectable Market Size (2020-2031)
2.1.2 Intravitreal Injectable Market Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Intravitreal Injectable by Country/Region (2020, 2024 & 2031)
2.2 Intravitreal Injectable Segment by Drug
2.2.1 Anti-VEGF
2.2.2 Steroids
2.2.3 Others
2.3 Intravitreal Injectable Market Size by Drug
2.3.1 Intravitreal Injectable Market Size CAGR by Drug (2020 VS 2024 VS 2031)
2.3.2 Global Intravitreal Injectable Market Size Market Share by Drug (2020-2025)
2.4 Intravitreal Injectable Segment by Disease
2.4.1 Macular Degeneration
2.4.2 Macular Edema
2.4.3 Uveitis
2.4.4 Retinal Vein Occlusion
2.4.5 Others
2.5 Intravitreal Injectable Market Size by Disease
2.5.1 Intravitreal Injectable Market Size CAGR by Disease (2020 VS 2024 VS 2031)
2.5.2 Global Intravitreal Injectable Market Size Market Share by Disease (2020-2025)
3 Intravitreal Injectable Market Size by Player
3.1 Intravitreal Injectable Market Size Market Share by Player
3.1.1 Global Intravitreal Injectable Revenue by Player (2020-2025)
3.1.2 Global Intravitreal Injectable Revenue Market Share by Player (2020-2025)
3.2 Global Intravitreal Injectable Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Intravitreal Injectable by Region
4.1 Intravitreal Injectable Market Size by Region (2020-2025)
4.2 Global Intravitreal Injectable Annual Revenue by Country/Region (2020-2025)
4.3 Americas Intravitreal Injectable Market Size Growth (2020-2025)
4.4 APAC Intravitreal Injectable Market Size Growth (2020-2025)
4.5 Europe Intravitreal Injectable Market Size Growth (2020-2025)
4.6 Middle East & Africa Intravitreal Injectable Market Size Growth (2020-2025)
5 Americas
5.1 Americas Intravitreal Injectable Market Size by Country (2020-2025)
5.2 Americas Intravitreal Injectable Market Size by Drug (2020-2025)
5.3 Americas Intravitreal Injectable Market Size by Disease (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Intravitreal Injectable Market Size by Region (2020-2025)
6.2 APAC Intravitreal Injectable Market Size by Drug (2020-2025)
6.3 APAC Intravitreal Injectable Market Size by Disease (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Intravitreal Injectable Market Size by Country (2020-2025)
7.2 Europe Intravitreal Injectable Market Size by Drug (2020-2025)
7.3 Europe Intravitreal Injectable Market Size by Disease (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Intravitreal Injectable by Region (2020-2025)
8.2 Middle East & Africa Intravitreal Injectable Market Size by Drug (2020-2025)
8.3 Middle East & Africa Intravitreal Injectable Market Size by Disease (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Intravitreal Injectable Market Forecast
10.1 Global Intravitreal Injectable Forecast by Region (2026-2031)
10.1.1 Global Intravitreal Injectable Forecast by Region (2026-2031)
10.1.2 Americas Intravitreal Injectable Forecast
10.1.3 APAC Intravitreal Injectable Forecast
10.1.4 Europe Intravitreal Injectable Forecast
10.1.5 Middle East & Africa Intravitreal Injectable Forecast
10.2 Americas Intravitreal Injectable Forecast by Country (2026-2031)
10.2.1 United States Market Intravitreal Injectable Forecast
10.2.2 Canada Market Intravitreal Injectable Forecast
10.2.3 Mexico Market Intravitreal Injectable Forecast
10.2.4 Brazil Market Intravitreal Injectable Forecast
10.3 APAC Intravitreal Injectable Forecast by Region (2026-2031)
10.3.1 China Intravitreal Injectable Market Forecast
10.3.2 Japan Market Intravitreal Injectable Forecast
10.3.3 Korea Market Intravitreal Injectable Forecast
10.3.4 Southeast Asia Market Intravitreal Injectable Forecast
10.3.5 India Market Intravitreal Injectable Forecast
10.3.6 Australia Market Intravitreal Injectable Forecast
10.4 Europe Intravitreal Injectable Forecast by Country (2026-2031)
10.4.1 Germany Market Intravitreal Injectable Forecast
10.4.2 France Market Intravitreal Injectable Forecast
10.4.3 UK Market Intravitreal Injectable Forecast
10.4.4 Italy Market Intravitreal Injectable Forecast
10.4.5 Russia Market Intravitreal Injectable Forecast
10.5 Middle East & Africa Intravitreal Injectable Forecast by Region (2026-2031)
10.5.1 Egypt Market Intravitreal Injectable Forecast
10.5.2 South Africa Market Intravitreal Injectable Forecast
10.5.3 Israel Market Intravitreal Injectable Forecast
10.5.4 Turkey Market Intravitreal Injectable Forecast
10.6 Global Intravitreal Injectable Forecast by Drug (2026-2031)
10.7 Global Intravitreal Injectable Forecast by Disease (2026-2031)
10.7.1 GCC Countries Market Intravitreal Injectable Forecast
11 Key Players Analysis
11.1 Regeneron Pharmaceuticals (Eylea)
11.1.1 Regeneron Pharmaceuticals (Eylea) Company Information
11.1.2 Regeneron Pharmaceuticals (Eylea) Intravitreal Injectable Product Offered
11.1.3 Regeneron Pharmaceuticals (Eylea) Intravitreal Injectable Revenue, Gross Margin and Market Share (2020-2025)
11.1.4 Regeneron Pharmaceuticals (Eylea) Main Business Overview
11.1.5 Regeneron Pharmaceuticals (Eylea) Latest Developments
11.2 Allergan
11.2.1 Allergan Company Information
11.2.2 Allergan Intravitreal Injectable Product Offered
11.2.3 Allergan Intravitreal Injectable Revenue, Gross Margin and Market Share (2020-2025)
11.2.4 Allergan Main Business Overview
11.2.5 Allergan Latest Developments
11.3 EyePoint Pharmaceuticals
11.3.1 EyePoint Pharmaceuticals Company Information
11.3.2 EyePoint Pharmaceuticals Intravitreal Injectable Product Offered
11.3.3 EyePoint Pharmaceuticals Intravitreal Injectable Revenue, Gross Margin and Market Share (2020-2025)
11.3.4 EyePoint Pharmaceuticals Main Business Overview
11.3.5 EyePoint Pharmaceuticals Latest Developments
11.4 Genentech
11.4.1 Genentech Company Information
11.4.2 Genentech Intravitreal Injectable Product Offered
11.4.3 Genentech Intravitreal Injectable Revenue, Gross Margin and Market Share (2020-2025)
11.4.4 Genentech Main Business Overview
11.4.5 Genentech Latest Developments
11.5 Kanghong Pharmaceutical
11.5.1 Kanghong Pharmaceutical Company Information
11.5.2 Kanghong Pharmaceutical Intravitreal Injectable Product Offered
11.5.3 Kanghong Pharmaceutical Intravitreal Injectable Revenue, Gross Margin and Market Share (2020-2025)
11.5.4 Kanghong Pharmaceutical Main Business Overview
11.5.5 Kanghong Pharmaceutical Latest Developments
11.6 Astellas Pharma
11.6.1 Astellas Pharma Company Information
11.6.2 Astellas Pharma Intravitreal Injectable Product Offered
11.6.3 Astellas Pharma Intravitreal Injectable Revenue, Gross Margin and Market Share (2020-2025)
11.6.4 Astellas Pharma Main Business Overview
11.6.5 Astellas Pharma Latest Developments
11.7 Clearside Biomedical
11.7.1 Clearside Biomedical Company Information
11.7.2 Clearside Biomedical Intravitreal Injectable Product Offered
11.7.3 Clearside Biomedical Intravitreal Injectable Revenue, Gross Margin and Market Share (2020-2025)
11.7.4 Clearside Biomedical Main Business Overview
11.7.5 Clearside Biomedical Latest Developments
11.8 Bayer
11.8.1 Bayer Company Information
11.8.2 Bayer Intravitreal Injectable Product Offered
11.8.3 Bayer Intravitreal Injectable Revenue, Gross Margin and Market Share (2020-2025)
11.8.4 Bayer Main Business Overview
11.8.5 Bayer Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂